Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling

Cell Proliferation

Volumn 48, Issue 2, 2015, Pages 249-258

  Zhang, Kun ^a   Song, Haixing ^a   Yang, Ping ^a   Dai, Xiaozhen ^a   Li, Ya ^a   Wang, Lan ^a   Du, Jun ^b   Pan, Kejian ^a   Zhang, Tao ^a  

^a CHENGDU MEDICAL COLLEGE   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; DISHEVELLED 1; GLYCOGEN SYNTHASE KINASE 3BETA; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; DISHEVELLED PROTEINS; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; CANCER RESISTANCE; CELL MEMBRANE; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IC50; IMMUNOFLUORESCENCE; MTT ASSAY; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ACTIVE TRANSPORT; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; RNA INTERFERENCE; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ACTIVE TRANSPORT, CELL NUCLEUS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BETA CATENIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 84923839626     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12161     Document Type: Article

References (56)

1. Rasool N, LaRochelle W, Zhong H, Ara G, Cohen J, Kohn EC (2010) Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells. Clin. Cancer Res. 16, 600-609.
2. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108.
3. Permuth-Wey J, Sellers TA (2009) Epidemiology of ovarian cancer. Methods Mol. Biol. 472, 413-437.
4. Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3, 502-516.
5. Chen X, Zhang J, Zhang Z, Li H, Cheng W, Liu J (2013) Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum. Pathol. 44, 2373-2384.
6. Li N, Hou JL, Shi ZZ, Li XG, Sun YC, Xu X et al. (2014) Copy number changes of 4-gene set may predict early relapse in advanced epithelial ovarian cancer after initial platinum-paclitaxel chemotherapy. Am. J. Cancer Res. 4, 285-292.
7. Morgan SL, Medina JE, Taylor MM, Dinulescu DM (2014) Targeting platinum resistant disease in ovarian cancer. Curr. Med. Chem. 21, 3009-3020.
8. Vergara D, Tinelli A, Iannone A, Maffia M (2012) The impact of proteomics in the understanding of the molecular basis of Paclitaxel-resistance in ovarian tumors. Curr. Cancer Drug Targets 12, 987-997.
9. Sedlakova I, Laco J, Tosner J, Caltova K, Cervinka M, Rezac A et al. (2012) Proteins of resistance and drug resistance in ovarian carcinoma patients. Klin Onkol. 25, 457-463.
10. Kovalev AA, Tsvetaeva DA, Grudinskaja TV (2013) Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp. Oncol. 35, 287-290.
11. Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F (2006) The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets 7, 893-909.
12. Lopez J, Banerjee S, Kaye SB (2013) New developments in the treatment of ovarian cancer - future perspectives. Ann. Oncol. 24(Suppl 10), x69-x76.
13. Suh DH, Kim MK, No JH, Chung HH, Song YS (2011) Metabolic approaches to overcoming chemoresistance in ovarian cancer. Ann. N. Y. Acad. Sci. 1229, 53-60.
14. Malaguarnera R, Belfiore A (2014) The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front. Endocrinol. (Lausanne) 5, 10.
15. Haass NK, Beaumont KA, Hill DS, Anfosso A, Mrass P, Munoz MA et al. (2014) Real-time cell cycle imaging during melanoma growth, invasion, and drug response. Pigment Cell Melanoma Res. 27, 764-776.
16. Kapse-Mistry S, Govender T, Srivastava R, Yergeri M (2014) Nanodrug delivery in reversing multidrug resistance in cancer cells. Front. Pharmacol. 5, 159.
17. Chau WK, Ip CK, Mak AS, Lai HC, Wong AS (2013) c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene 32, 2767-2781.
18. Kim SH, Juhnn YS, Song YS (2007) Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann. N. Y. Acad. Sci. 1095, 82-89.
19. MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9-26.
20. Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H et al. (2010) Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res. 30, 2041-2048.
21. Li Q, Dashwood WM, Zhong X, Nakagama H, Dashwood RH (2007) Bcl-2 overexpression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving beta-catenin, c-Myc and E2F1. Oncogene 26, 6194-6202.
22. Aschenbach WG, Ho RC, Sakamoto K, Fujii N, Li Y, Kim YB et al. (2006) Regulation of dishevelled and beta-catenin in rat skeletal muscle: an alternative exercise-induced GSK-3beta signaling pathway. Am. J. Physiol. Endocrinol. Metab. 291, E152-E158.
23. Lim JC, Kania KD, Wijesuriya H, Chawla S, Sethi JK, Pulaski L et al. (2008) Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J. Neurochem. 106, 1855-1865.
24. Sutton LP, Rushlow WJ (2012) The dopamine D2 receptor regulates Akt and GSK-3 via Dvl-3. Int. J. Neuropsychopharmacol. 15, 965-979.
25. Fukumoto S, Hsieh CM, Maemura K, Layne MD, Yet SF, Lee KH et al. (2001) Akt participation in the Wnt signaling pathway through Dishevelled. J. Biol. Chem. 276, 17479-17483.
26. Zhao Y, Yang ZQ, Wang Y, Miao Y, Liu Y, Dai SD et al. (2010) Dishevelled-1 and dishevelled-3 affect cell invasion mainly through canonical and noncanonical Wnt pathway, respectively, and associate with poor prognosis in nonsmall cell lung cancer. Mol. Carcinog. 49, 760-770.
27. You L, Xu Z, Punchihewa C, Jablons DM, Fujii N (2008) Evaluation of a chemical library of small-molecule Dishevelled antagonists that suppress tumor growth by down-regulating T-cell factor-mediated transcription. Mol. Cancer Ther. 7, 1633-1638.
28. Mizutani K, Miyamoto S, Nagahata T, Konishi N, Emi M, Onda M (2005) Upregulation and overexpression of DVL1, the human counterpart of the Drosophila dishevelled gene, in prostate cancer. Tumori 91, 546-551.
29. He L, Zhao C, Yan M, Zhang LY, Xia YZ (2009) Inhibition of P-glycoprotein function by procyanidine on blood-brain barrier. Phytother. Res. 23, 933-937.
30. Nagahata T, Shimada T, Harada A, Nagai H, Onda M, Yokoyama S et al. (2003) Amplification, up-regulation and over-expression of DVL-1, the human counterpart of the Drosophila disheveled gene, in primary breast cancers. Cancer Sci. 94, 515-518.
31. Metcalfe C, Mendoza-Topaz C, Mieszczanek J, Bienz M (2010) Stability elements in the LRP6 cytoplasmic tail confer efficient signalling upon DIX-dependent polymerization. J. Cell Sci. 123, 1588-1599.
32. Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D et al. (2009) The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 28, 2245-2256.
33. Hong Y, Yang J, Wu W, Wang W, Kong X, Wang Y et al. (2008) Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells. Biochim. Biophys. Acta 1782, 649-657.
34. Cheng L, Zhang C, Li D, Zou J, Wang J (2014) Transforming growth factor-beta1 (TGF-beta1) induces mouse precartilaginous stem cell proliferation through TGF-beta receptor II (TGFRII)-Akt-beta-catenin signaling. Int. J. Mol. Sci. 15, 12665-12676.
35. Zhu X, Wang S, Yu L, Yang H, Tan R, Yin K et al. (2014) TL-2 attenuates beta-amyloid induced neuronal apoptosis through the AKT/GSK-3beta/beta-catenin pathway. Int. J. Neuropsychopharmacol. 17, 1511-1519.
36. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34-43.
37. Suh DH, Kim JW, Kang S, Kim HJ, Lee KH (2014) Major clinical research advances in gynecologic cancer in 2013. J. Gynecol. Oncol. 25, 236-248.
38. Steffensen KD, Smoter M, Waldstrom M, Grala B, Bodnar L, Stec R et al. (2014) Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression. Int. J. Oncol. 44, 1736-1744.
39. Shang D, Liu Y, Xu X, Han T, Tian Y (2011) 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-beta-catenin expression. Cancer Lett. 311, 230-236.
40. Arend RC, Londono-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B et al. (2014) Inhibition of Wnt/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecol. Oncol. 134, 112-120.
41. Rosenbluh J, Wang X, Hahn WC (2014) Genomic insights into WNT/beta-catenin signaling. Trends Pharmacol. Sci. 35, 103-109.
42. Gao C, Chen YG (2010) Dishevelled: the hub of Wnt signaling. Cell. Signal. 22, 717-727.
43. Schwarz-Romond T, Fiedler M, Shibata N, Butler PJ, Kikuchi A, Higuchi Y et al. (2007) The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. Nat. Struct. Mol. Biol. 14, 484-492.
44. Schwarz-Romond T, Metcalfe C, Bienz M (2007) Dynamic recruitment of axin by Dishevelled protein assemblies. J. Cell Sci. 120, 2402-2412.
45. Pulvirenti T, Van Der Heijden M, Droms LA, Huse JT, Tabar V, Hall A (2011) Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas. Cancer Res. 71, 7280-7290.
46. Wong HC, Bourdelas A, Krauss A, Lee HJ, Shao Y, Wu D et al. (2003) Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. Mol. Cell 12, 1251-1260.
47. Punchihewa C, Ferreira AM, Cassell R, Rodrigues P, Fujii N (2009) Sequence requirement and subtype specificity in the high-affinity interaction between human frizzled and dishevelled proteins. Protein Sci. 18, 994-1002.
48. Ieiri I (2012) Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab. Pharmacokinet. 27, 85-105.
49. Choudhuri S, Klaassen CD (2006) Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25, 231-259.
50. Dai H, Ding H, Meng XW, Lee SH, Schneider PA, Kaufmann SH (2013) Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. Cancer Res. 73, 6998-7008.
51. Shen DY, Zhang W, Zeng X, Liu CQ (2013) Inhibition of Wnt/beta-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma. Cancer Sci. 104, 1303-1308.
52. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D et al. (2010) β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18, 606-618.
53. Ruel L, Stambolic V, Ali A, Manoukian AS, Woodgett JR (1999) Regulation of the protein kinase activity of Shaggy(Zeste-white3) by components of the wingless pathway in Drosophila cells and embryos. J. Biol. Chem. 274, 21790-21796.
54. Cook D, Fry MJ, Hughes K, Sumathipala R, Woodgett JR, Dale TC (1996) Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling pathway which involves a protein kinase C. EMBO J. 15, 4526-4536.
55. Arend RC, Londono-Joshi AI, Straughn JM Jr, Buchsbaum DJ (2013) The Wnt/beta-catenin pathway in ovarian cancer: a review. Gynecol. Oncol. 131, 772-779.
56. Bishnupuri KS, Sainathan SK, Bishnupuri K, Leahy DR, Luo Q, Anant S et al. (2014) Reg4-induced mitogenesis involves Akt-GSK3beta-beta-Catenin-TCF-4 signaling in human colorectal cancer. Mol. Carcinog. 53(Suppl 1), E169-E180.